In theca cells, there was no difference in mRNA expression for CYP17A1, HSD3B2 and STAR between dominant follicles treated with saralasin or vehicle during follicular deviation (FERREIRA et al., 2011a).
Experiment 3 was conducted to investigate if Ang II role on bovine theca cells steroidogenesis cells is affected in the presence of an Ang II receptors antagonist (saralasin).
Additionally, it was observed a significant decrease in mRNA abundance for the enzyme CYP19A1 in granulosa cells of dominant follicles after intrafollicular injection of saralasin (FERREIRA et al., 2011a).
Indeed, the intrafollicular injection of saralasin in the dominant follicle did not reduce CYP17A1 expression, which is in agreement with findings in the present study showing that Ang II do not increase CYP17A1 mRNA expression in LH-treated cells.
(2011a) in bovine theca cells treat with saralasin. However, variances in the experimental conditions, such as the reproductive status and metabolism of the cows used for cell collection, might have accounted for the nonhomogenous findings.